secwatch.observer — SEC 8-K summary
======================================

Issuer:     INOVIO PHARMACEUTICALS, INC. (INO)
CIK:        0001055726
Form:       8-K
Filed at:   2025-03-18T23:59:59+00:00
Accession:  0001055726-25-000013
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Inovio reports FY2024 net loss $107.3M; on track for INO-3107 BLA submission mid-2025
--------------------------------------------------------------------------------

- Net loss $19.4M Q4 ($0.65/share) and $107.3M FY ($3.95/share), narrower than 2023's $135.1M.
- Cash, equivalents & investments $94.1M at Dec 31, 2024, down from $145.3M at Dec 31, 2023.
- BLA for INO-3107 (RRP) on track for rolling submission mid-2025; device verification testing complete H1 2025.
- DMAb interim data: 100% of participants (24/24) maintained antibody levels at week 72; no anti-drug antibodies.
- Raised >$72M from ATM and two equity offerings in 2024; cash runway into Q1 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1055726/000105572625000013/0001055726-25-000013-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1055726/000105572625000013/ino-20250318.htm
  HTML page:      https://secwatch.observer/filing/0001055726-25-000013

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer